Free Trial
NASDAQ:CTXR

Citius Pharmaceuticals Q3 2023 Earnings Report

Citius Pharmaceuticals logo
$1.56 -0.07 (-4.29%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.60 +0.04 (+2.88%)
As of 07/11/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Pharmaceuticals EPS Results

Actual EPS
-$1.50
Consensus EPS
-$1.50
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Citius Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Citius Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Sunday, August 13, 2023
Conference Call Time
6:00PM ET

Upcoming Earnings

Citius Pharmaceuticals' Q3 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Citius Pharmaceuticals Earnings Headlines

CTXR - Citius Pharmaceuticals Inc Ownership - Morningstar
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Citius Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Pharmaceuticals and other key companies, straight to your email.

About Citius Pharmaceuticals

Citius Pharmaceuticals (NASDAQ:CTXR) is a clinical‐stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products for hospital acute care and cancer supportive care settings. The company’s product pipeline addresses severe and often life‐threatening conditions, including catheter‐related bloodstream infections, acute respiratory distress syndrome and mucosal immunotherapy for gastrointestinal infections. By focusing on hospital‐administered therapies, Citius seeks to meet unmet medical needs where rapid intervention and novel mechanisms of action can improve patient outcomes and reduce healthcare costs.

The company’s lead product candidate, Mino‐Lok®, is an antibiotic lock solution designed to treat patients suffering from catheter‐related bloodstream infections without the need for catheter removal. Citius is also developing Mino‐Wrap®, an antibiotic‐eluting mesh intended for use in surgical wound sites to prevent post‐operative infections. In parallel, the company is advancing DSTAT®, a recombinant form of human deoxyribonuclease I for the treatment of acute respiratory distress syndrome (ARDS), and evaluating hyperimmune compounds targeting recurrent Clostridioides difficile infection under its proprietary HyperAcute® platform.

Founded in 2015 through the combination of multiple pharmaceutical ventures, Citius is headquartered in Cranford, New Jersey, and conducts clinical trials and manufacturing partnerships in the United States, with potential expansion into international markets through licensing collaborations. Since its inception, the company has pursued an asset‐centric model, favoring targeted in‐licensing of technologies and strategic alliances to accelerate development timelines and manage capital efficiently.

Under the leadership of President and Chief Executive Officer Michael Mulhern and a management team experienced in product development, regulatory affairs and commercialization, Citius Pharmaceuticals aims to navigate late‐stage clinical programs toward regulatory approval. The company continues to engage with healthcare providers, regulatory authorities and potential partners to bring its innovative therapies to the patients who need them most.

View Citius Pharmaceuticals Profile

More Earnings Resources from MarketBeat